Effectiveness of Oral Albendazole in the Treatment of Severe Acute Malnutrition
Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Benefit of Antihelminthic Therapy in the Community-Based Treatment of Severe Acute Malnutrition in Malawian Children
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Blantyre, Malawi
- St. Louis Nutrition Project
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 12-59 months old
- Kwashiorkor and/or Marasmus
- Qualified for home-based therapeutic feeding with RUTF
Exclusion Criteria:
- Obvious congenital or other malformation that makes child a poor candidate for feeding with RUTF
- Unable to consume test-dose of RUTF in clinic
- Parent refusal to participate and return for follow-up
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
placebo given once
|
|
Experimental: Albendazole
|
single dose albendazole given at the time of enrollment
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
nutritional recovery
Time Frame: 12 weeks
|
Weight-for-Height Z-score (WHZ) > -2 without bipedal pitting edema
|
12 weeks
|
|
mortality
Time Frame: 12 weeks
|
12 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
malnutrition relapse
Time Frame: 6 months
|
acute malnutrition, either moderate (WHZ < -2) or severe (WHZ < -3 and/or bipedal pitting edema)
|
6 months
|
|
height and weight gain
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Kenneth Maleta, MBBS PhD, University of Malawi
- Principal Investigator: Mark J Manary, MD, University of Malawi
- Study Director: Indi Trehan, MD MPH DTM&H, University of Malawi
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nutrition Disorders
- Deficiency Diseases
- Protein Deficiency
- Malnutrition
- Severe Acute Malnutrition
- Protein-Energy Malnutrition
- Kwashiorkor
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antiprotozoal Agents
- Antiparasitic Agents
- Anthelmintics
- Antiplatyhelmintic Agents
- Anticestodal Agents
- Albendazole
Other Study ID Numbers
Other Study ID Numbers
- MJM-albendazole
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.